Treosulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC

International Journal of Hematology

Volumn 90, Issue 5, 2009, Pages 571-575

  Klaudel Dreszler, Maja Agnieszka ^a   Kalwak, Krzysztof ^b   Kurenko Deptuch, Magdalena ^a   Wolska Kusnierz, Beata ^a   Heropolitanska Pliszka, Edyta ^a   Pietrucha, Barbara ^a   Mikoluc, Bozena ^c   Gorczyńska, Ewa ^b   Ussowicz, Marek ^b   Chybicka, Alicja ^b   Bernatowska, Ewa ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Invasive aspergillosis; Peripheral blood stem cell transplantation; Primary immunodeficiency; Treosulfan

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; ITRACONAZOLE; MELPHALAN; METHOTREXATE; STEROID; THYMOCYTE ANTIBODY; TREOSULFAN; VORICONAZOLE;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ANTIFUNGAL RESISTANCE; ANURIA; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CASE REPORT; CHILD; CHRONIC GRANULOMATOUS DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENCE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ECHOGRAPHY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRANULOCYTE PRECURSOR; GRANULOCYTOPENIA; HEMATURIA; HEPATOMEGALY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HIGH RISK PATIENT; HISTOPATHOLOGY; HLA MATCHING; HUMAN; IDIOPATHIC PULMONARY SYNDROME; INFECTION PREVENTION; INFLAMMATION; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; LUNG FIBROSIS; LUNG GRANULOMA; LUNG INFILTRATE; LYMPHADENOPATHY; MALE; MEDIASTINUM LYMPH NODE; MONOTHERAPY; MUCOSA INFLAMMATION; ORGAN DONOR; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHYSICAL EXAMINATION; PRESCHOOL CHILD; REDUCED INTENSITY CONDITIONING; TACHYCARDIA; THORACOTOMY; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; ASPERGILLOSIS; BUSULFAN; CHILD, PRESCHOOL; GRAFT SURVIVAL; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REOPERATION; TRANSPLANTATION CONDITIONING;

EID: 73449103154     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0433-z     Document Type: Article

References (24)

1. BH Segal TL Leto JI Gallin HL Malech SM Holland 2000 Genetic, biochemical and clinical features of CGD Medicine (Baltimore) 79 170 200 10.1097/00005792-200005000-00004 1:CAS:528:DC%2BD3cXktFGjt7s%3D (Pubitemid 30327531)
2. JA Winkelstein MC Marino RB Johnston Jr J Boyle J Curnutte JI Gallin, et al. 2000 Chronic granulomatous disease. Report on national registry of 368 patients Medicine (Baltimore) 79 155 169 10.1097/00005792-200005000-00003 1:STN:280:DC%2BD3czgtlemtg%3D%3D (Pubitemid 30327530)
3. DM Margolis DA Melnick DW Alling JI Gallin 1990 Trimethoprim- sulfametoxazole prophylaxis in the management of chronic granulomatous disease J Infect Dis 162 723 726 1:STN:280:DyaK3czlsVOitA%3D%3D 2117627
4. SD Rosenzweig SM Holland 2004 Phagocyte immunodeficiencies and their infections Allergy Clin Immunol 113 620 626 10.1016/j.jaci.2004.02.001 1:CAS:528:DC%2BD2cXjt1alsbk%3D (Pubitemid 38530414)
5. JI Gallin DW Alling HL Malech R Wesley D Koziol B Marciano, et al. 2003 Itraconazole to prevent fungal infectons in chronic granulomatous disease N Engl J Med 348 2416 2422 10.1056/NEJMoa021931 1:CAS:528:DC%2BD3sXksFKgur8%3D 12802027 (Pubitemid 36682820)
6. ME Horwitz AJ Barrett MR Brown CS Carter R Childs JI Gallin, et al. 2001 Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft N Engl J Med 344 926 927 10.1056/NEJM200103223441210 (Pubitemid 32224403)
7. T Güngör J Halter A Klink S Junge KD Stumpe R Seger, et al. 2005 Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients Transplantation 79 1596 1606 10.1097/01.TP.0000163466.73485.5E 15940051 (Pubitemid 40847593)
8. NG Almyroudis SM Holland BH Segal 2005 Invasive aspergillosis in primary immunodeficiencies Med Mycol 43 Suppl I S247 S259 10.1080/13693780400025203 16110817 (Pubitemid 41038575)
9. R Herbrecht DW Denning TF Patterson JE Bennett RE Greene JW Oestmann, et al. 2002 Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 408 415 10.1056/NEJMoa020191 1:CAS:528: DC%2BD38XlvFKrt7o%3D 12167683 (Pubitemid 34851833)
10. DW Denning P Ribaud N Milpied D Caillot R Herbrecht E Thiel, et al. 2002 Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 563 571 10.1086/324620 1:CAS:528: DC%2BD38XitlCitbg%3D 11807679 (Pubitemid 34165316)
11. TJ Walsh I Lutsar T Driscoll B Dupont M Roden P Ghahramani, et al. 2002 Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children Pediatr Infect Dis J 21 240 248 10.1097/00006454-200203000-00015 12005089 (Pubitemid 34214142)
12. J Maertens 2006 Caspofungin: an advanced treatment approach for suspected or confirmed invasive aspergillosis Int J Antimicrob Agents 27 457 467 10.1016/j.ijantimicag.2006.03.019 1:CAS:528:DC%2BD28XltFCgtr8%3D 16701980 (Pubitemid 43767076)
13. AH Groll A Attarbaschi FR Schuster N Herzog L Grigull MN Dworzak, et al. 2006 Treatment with caspofungin in immunocompromised pediatric patients: a multicentre survey J Antimicrob Chemother 57 527 535 10.1093/jac/dkl009 1:CAS:528:DC%2BD28XhtlOguro%3D 16431856 (Pubitemid 43245429)
14. TJ Walsh JL Goodman P Pappas I Bekersky DN Buell M Roden, et al. 2001 Safety, tolerance and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus sp. and other filamentous fungi: maximum tolerated dose study Antimicrob Agents Chemother 45 3487 3496 10.1128/AAC.45.12.3487-3496.2001 1:CAS:528:DC%2BD3MXovVOltLc%3D 11709329 (Pubitemid 33107867)
15. G Massenkeil S Rackwitz I Genvresse O Rosen B Dörken R Arnold 2002 Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation Bone Marrow Transplant 30 899 903 10.1038/sj.bmt.1703737 1:STN:280:DC%2BD38jhtlagtw%3D%3D 12476283 (Pubitemid 36097479)
16. JM Rappeport PE Newburger RM Goldblum AS Goldman DG Nathan R Parkman 1982 Allogeneic bone marrow transplantation for chronic granulomatous disease J Pediatr 101 952 955 10.1016/S0022-3476(82)80017-6 1:STN:280: DyaL3s%2FlvFWgtQ%3D%3D 6754900 (Pubitemid 13253252)
17. N Kamani CS August SD Douglas E Burkey A Etzioni HW Lischner 1984 Bone marrow transplantation in chronic granulomatous disease J Pediatr 105 42 46 10.1016/S0022-3476(84)80354-6 1:STN:280:DyaL2c3kt1Wrug%3D%3D 6376746 (Pubitemid 14086267)
18. RA Seger T Gungor BH Belohradsky S Blanche P Bordigoni P Di Bartolomeo, et al. 2002 Treatment of chronic granulomatous disease with myeloablative conditioning and unmodified hemopoietic allograft: a survey of the European experience Blood 100 1985 2000 10.1182/blood-2002-02-0583 (Pubitemid 35429672)
19. H Ozsahin M von Planta I Müller HC Steinert D Nadal R Lauener, et al. 1998 Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B Blood 92 8 2719 2724 1:CAS:528:DyaK1cXms1elt7s%3D 9763555
20. B Bielorai A Toren B Wolach M Mandel H Golan Y Neumann, et al. 2000 Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation Bone Marrow Transplant 26 1025 1028 10.1038/sj.bmt.1702651 1:STN:280:DC%2BD3M7kt1GmsA%3D%3D 11100285
21. B Greystoke S Bonanomi TF Carr M Gharib T Khalid M Coussons, et al. 2008 Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities Br J Haematol 142 257 262 10.1111/j.1365-2141. 2008.07064.x 1:CAS:528:DC%2BD1cXpslGrtLg%3D 18492115 (Pubitemid 351987307)
22. Bernardo ME, Zecca M, Piras E, Vacca A, Giorgani G, Cugno, et al. Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with thalassemia major. Br J Haematol. 2008;143(4): 548-51.
23. J Casper W Knauf T Kiefer D Wolff B Steiner U Hammer, et al. 2004 Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation Blood 103 2 725 731 10.1182/blood-2002-11-3615 1:CAS:528:DC%2BD2cXmsFCgug%3D%3D 12947008 (Pubitemid 38140111)
24. DW Beelen R Trenschel J Casper M Freund RA Hilger ME Scheulen, et al. 2005 Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications Bone Marrow Transplant 35 233 241 10.1038/sj.bmt.1704784 1:CAS:528:DC%2BD2MXmslOguw%3D%3D 15592494 (Pubitemid 40268293)